Clinical Trial Update: Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use. [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy and safety of pregabalin versus placebo for generalized anxiety disorder in subjects discontinuing benzodiazepines, with 6 week…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• Pregabalin (Pregabalin)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Generalized Anxiety Disorder | Phase 3 | Status: COMPLETED | Results posted: 2009-11-09